← All trials
NCT07088380
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2025
- Primary completion
- Feb 28, 2026
- Completion date
- Feb 28, 2026
- First posted
- Jul 28, 2025
- Last posted
- Jul 29, 2025
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vita-Salute University of Milano. ItalyLead sponsor
- Vita-Salute University of Milano. ItalySponsor investigator
- Vita-Salute University of Milano. ItalyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.